CB-03-01 for anti-hair loss is a molecule that acts at the level of the skin androgen receptor, blocking dihydrotestosterone (DHT) from binding to the receptor in the cell. The molecule CB-03-01 for anti-hair loss has a unique mechanism that acts at the skin surface, and is quickly metabolized to free inactive cortexolone, a substance naturally found in the body. The molecule CB-03-01 for anti-hair loss has been evaluated in a variety of animal models as well as initial human trials in Europe for acne and androgenic alopecia. The results of these studies demonstrate that CB-03-01 appears to have potent anti-androgenic activity without significant local or systemic side effects.
In 2015, the Italian company (Cosmo Pharmaceuticals) that was compounding CB-03-01 changed the product’s name to the unusual Breezula. Moreover, Cosmo itself was renamed as Cassiopeia. I wrote about those developments here.
95 patients were enrolled in a double blind study that lasted for 6 months and ended in December 2015.
31 patients were on Breezula 5%, 31 patients were on Minoxidil 5% and 33 patients were given nothing except a vehicle (i.e., placebo).
Of the 95 patients, 78 lasted till the end of the 6-month treatment period, and 73 of those were deemed to have completed the protocol without any violations. Of those 73 patients, 23 were on Breezula, 25 were on Minoxidil and 25 were on a placebo. CB-03-01 for anti-hair loss A fairly even distribution.
39 percent of patients on Breezula had at least some improvement in hair growth,CB-03-01 for anti-hair loss compared to 36 percent of those on Minoxidil. 26 percent of patients on Breezula had at least some worsening in hair growth, compared to 16 percent of those on Minoxidil. Status quo was maintained in 35 percent of Breezula patients versus 48 percent of Minoxidil patients.
Later in 2016, Cassiopeia will commence further dosing related trials for Breezula. I wonder if they will compare the effectiveness of higher doses to the effectiveness of the much more rarely used Minoxidil 15%?
Overall, Breezula seems as good as Minoxidil, and since the latter is not an anti-androgen, we can use both products topically on our scalp for two separate positive effects. Perhaps we can also add topical Bimatoprost and topical Finasteride to that combo later this year, and then we would have a quartet of topical products, each tackling a different mechanism of balding.
Of course Breezula is still years from release (even if we assume they can speed up phase 3 trials like is the case in Japan, with newer regulations), but some people on hair loss forums are purchasing it illegally or even making it at home. I cannot ever recommend that. An even more optimistic scenario is the addition of Samumed’s topical SM04554 to the mix whenever that comes out. It would be funny if in 2020, I started applying a quintet of topical products CB-03-01 for anti-hair loss to my scalp and then suddenly a simple cure for hair loss came out that made all those topical products obsolete.
For younger people who have only been balding for a few years or less, such incremental developments are probably not too exciting.CB-03-01 for anti-hair loss For those of us who have been following the hair loss industry for many more years, it is very pleasing to finally see new products arriving. CB-03-01 for anti-hair loss is that there have only ever been two products officially FDA approved to tackle hair loss — 1) Finasteride and 2) Minoxidil.